First-in-Class Products:Non-Small Cell Lung Cancer Market - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

First-in-Class Products:Non-Small Cell Lung Cancer Market

Description:

The report will enable business development and enable marketing executives to strategize their product launches by allowing them to understand the focal shifts in molecular targets in the NSCLC pipeline For Further Details : – PowerPoint PPT presentation

Number of Views:24

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: First-in-Class Products:Non-Small Cell Lung Cancer Market


1
Frontier Pharma Non-Small Cell Lung Cancer
Market
2
Summary
Large Degree of Innovation in NSCLC Pipeline The
NSCLC pipeline currently has 389 products in
active development across all stages, but a stark
contrast between the mechanisms of action
employed in the current market and the pipeline
is evident. Where the market comprises primarily
ineffective chemotherapies that target tubulin or
DNA replication, the pipeline shows an incredibly
diverse range of therapies targeting multiple
signaling pathways and molecules integral to
cancer development. This diversity is partially
due to the presence of 122 first-in-class
products, which accounts for 38 of the overall
pipeline therapies that disclosed their target.
In an industry, market and development landscape
that favors first-in-class over
non-first-in-class development in many ways, such
as through faster approval or greater revenue,
this finding has strategic implications for a
wide array of market participants, both large and
small. Despite a high attrition rate in NSCLC,
first-in-class therapies that reach the market
have the potential to transform and improve the
NSCLC treatment landscape. For Further Details
http//www.bigmarketresearch.com/frontier-pharma-n
on-small-cell-lung-cancer-identifying-and-commerci
alizing-first-in-class-innovation-market
3
Report Description
  • Alignment of First-in-Class Molecular Target with
    Disease Causation
  • The method of characterizing NSCLC tumors is
    currently shifting from the traditional
    histology-based characterization to a more
    specific molecule-based method of
    characterization. This has resulted in the
    identification of key oncogenic mutations in
    NSCLC and has coincided with the rise of targeted
    pipeline therapies, which are designed to target
    proteins in signaling pathways that are
    frequently mutated, amplified or overexpressed in
    NSCLC. Aligning the molecular target with
    disease-causing signaling pathways and frequently
    mutated pathways therapies can benefit from
    reduced systemic cytotoxic effects while still
    inhibiting tumor-promoting signaling. Therefore,
    targeted therapies often display superior safety
    and efficacy to chemotherapies.
  • GBI Researchs proprietary analysis showed
    substantial variation in how well NSCLC
    first-in-class targets align to frequent gene
    mutations. Further in-depth analysis identified
    the most promising first-in-class targets based
    on various scientific and clinical parameters.
    Examining scientific and clinical data of
    promising first-in-class targets showed that
    first-in-class status is not, in its own right,
    enough for a successful product however, the
    first-in-class products substantiated by
    scientific and clinical evidence will be exciting
    future prospects with the potential to transform
    the NSCLC market.

4
Key Segment
  • First-in-Class Products in Licensing and
    Co-development Deals
  • The NSCLC deals landscape appears relatively
    quiet for such a large indication. However,
    analysis showed that of the therapies with
    disclosed deal values there is significant range
    in the value of NSCLC deals. Concerning
    first-in-class specifically, only five licensing
    or co-development deals have been made since
    2006. Despite the low sample size, it is clear
    that the first-in-class NSCLC products offer an
    attractive investment prospect as they command
    much higher deal values and, on average, deals
    occur earlier in development compared to
    non-first-in-class counterparts. Both trends were
    substantiated by industry-wide data that showed
    that, particularly in Phase I, first-in-class
    products would attract larger mean and median
    total deal values. The data highlight that the
    first-in-class deals landscape is different and
    indicates a greater chance of becoming much more
    lucrative than the deals landscape for
    addition-to-class or advance-in-class therapies.
  • A total of 117 first-in-class products that are
    currently in development have not yet been
    entered into a licensing or co-development deal.
    In a transforming market that will favor
    innovative, targeted therapies with a strong
    clinical record, there are numerous opportunities
    for strategic alliances to bolster a
    first-in-class portfolio or fund clinical
    development. Although not all are aligned to
    disease-causing signaling pathways, many are
    supported by robust scientific and clinical data,
    making them attractive prospects as both
    therapeutics and investment opportunities.

5
Scope
  • The report analyzes innovation in NSCLC in the
    context of the overall pipeline and current
    market landscape. It also analyzes the deals
    landscape surrounding first-in-class products and
    pinpoints in-licensing opportunities. The report
    includes
  • A brief introduction to NSCLC, including
    symptoms, pathophysiology, and an overview of
    pharmacotherapy and treatment algorithms
  • Extensive categorization of histological and
    molecular features of NSCLC tumors
  • Coverage of the changing molecular target
    landscape and particular points of innovation in
    the pipeline
  • A comprehensive review of the pipeline for
    first-in-class therapies, analyzed by stage of
    development, molecule type and molecular target
  • Identification and assessment of first-in-class
    molecular targets with a particular focus on
    early-stage programs of which clinical utility
    has yet to be evaluated, as well as literature
    reviews of novel molecular targets
  • An assessment of the licensing and co-development
    deal landscape for NSCLC therapies and
    benchmarking of deals comparing first-in-class
    and non-first-in-class-products
  • Read The Complete Report On http//www.bigmarket
    research.com/frontier-pharma-non-small-cell-lung-c
    ancer-identifying-and-commercializing-first-in-cla
    ss-innovation-market

6
Reasons to buy
  • The report will enable business development and
    enable marketing executives to strategize their
    product launches by allowing them to
  • Understand the focal shifts in molecular targets
    in the NSCLC pipeline
  • Understand the distribution of pipeline programs
    by phase of development, molecule type and
    molecular target
  • Access a scientific and clinical analysis of
    first-in-class developmental programs for NSCLC,
    benchmarked against non-first-in-class targets
  • Assess the valuations of licensed and
    co-developed NSCLC treatments
  • Access a list of the first-in-class therapies
    potentially open to deal-making opportunities
  • To Get More Details Enquire _at_ http//www.bigmarket
    research.com/report-enquiry/159536

7
Content
  • Table of Contents
  • Executive Summary
  • Clinical and Commercial Landscape
  • Assessment of Pipeline Product Innovation
  • Deals and Strategic Consolidations
  • Appendix
  • Read The Complete TOC _at_ http//www.bigmarketresear
    ch.com/frontier-pharma-non-small-cell-lung-cancer-
    identifying-and-commercializing-first-in-class-inn
    ovation-market

8
Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
(617) 674-4143 Toll Free 1 (855) 711-1555 Fax
1 (855) 550-5975 Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com
About PowerShow.com